PUBLISHER: Roots Analysis | PRODUCT CODE: 1737048
PUBLISHER: Roots Analysis | PRODUCT CODE: 1737048
As per Roots Analysis, the global autoinjectors market is estimated to grow from USD 90.6 billion in the current year to USD 175.9 billion by 2035, at a CAGR of 6.2% during the forecast period, till 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Usability
Route of Administration
Type of Molecule Delivered
Type of Actuation Mechanism
Volume of Container
End-user
Target Indication
Key Geographical Regions
The global rise in chronic diseases, such as diabetes, multiple sclerosis, rheumatoid arthritis and severe allergies, has driven a pressing requirement for a more efficient, innovative and user-friendly drug delivery systems. It is worth highlighting that the impact of these chronic conditions on patients is substantial, as the associated costs and complications can escalate dramatically over a period. As a result, the medical industry has made significant efforts in developing novel drug delivery devices, including autoinjectors.
Autoinjectors are automatic injection devices that are used for the delivery of drugs through the subcutaneous or intramuscular routes. These are primarily spring-driven devices that use prefilled syringes or cartridges as primary containers. By complete or partial automation of the drug delivery process, these devices make the dosing process more convenient. Owing to which, autoinjectors have demonstrated significant potential as the next generation of patient-centric devices, capable of safe and reliable delivery of injectables. Further, the advent of novel biologics is driving the demand for injection of higher viscosities of drugs in larger volumes. Consequently, many device manufacturers, such as BD Medical and SHL, have introduced large volume autoinjectors. Additionally, the new autoinjector devices, which are currently under development, are capable of addressing the specific needs and wants of individual patients. These are designed to enable adjustments in the dosage or features of the device based upon the requirements of the user. In fact, connecting the injectors digitally to various products and platforms is expected to improve adherence and quality of life for the patients. Given these advancements in autoinjectors, the growing need for effective drug delivery systems and disease management can be efficiently addressed in the future.
The report delves into the current state of the global autoinjectors market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. Presently, close to 150 autoinjectors are available / being manufactured by various players, globally; the majority of the autoinjector manufacturers are headquartered in North America.
2. Most of the commercially available autoinjectors are suitable for subcutaneous administration; these autoinjectors are integrated with audible and visual indicators and can deliver a myriad of molecules.
3. More than 50% of the deals in the autoinjectors domain were inked in the last three years; further, most of the intercontinental as well as intracontinental partnerships have been signed by players based in Europe.
4. Since 2019, more than 1,100 patents related to autoinjectors have been filed by / granted to various stakeholders to protect the intellectual property generated within this domain.
5. Several scientists, clinicians and industry veterans, affiliated to academic / medical / commercial organizations, are spearheading research related to autoinjectors.
6. Nearly 160 autoinjector combination products (with different drugs) have been approved by regulatory authorities, across the world; further, close to 60% of autoinjector combination product developers are very large players.
7. Around 75% of the commercialized autoinjector combination products are compatible with syringes; notably, majority of these combination products are intended to be used in homecare settings by adults.
8. More than 70 autoinjector combination products intended for the treatment of various indications are currently being evaluated in early and late stages of development; further, most of the developers for these products are publicly listed companies.
9. Around 90% of the early and late-stage combination products are currently in different clinical phases of development; majority of these are being developed for the treatment of chronic conditions (primarily rheumatoid arthritis).
10. The autoinjectors market is anticipated to grow at a steady rate; notably, disposable autoinjectors are likely to capture over 88% market share in 2024 as they eliminate the need for manual loading of medication and have lower risk of contamination.
11. Autoinjectors with automatic actuation mechanism are anticipated to grow at faster pace (~7%) till 2035; further, the autoinjectors intended for delivering drugs targeting rheumatoid arthritis are likely to dominate the current market.
12. The autoinjectors suitable for home care are likely to capture majority share in the market during the forecasted period; Asia-Pacific is anticipated to grow at higher rate in this domain, till 2035.
Disposable Autoinjectors Occupies the Largest Share of the Global Autoinjectors Market
Based on the usability, the market is segmented into disposable autoinjectors and reusable autoinjectors. At present, disposable autoinjectors segment hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the forthcoming years.
Autoinjectors for Intravenous Drug Delivery is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period
Based on the route of administration, the market is segmented into subcutaneous, intramuscular and intravenous routes. Currently, autoinjectors used for subcutaneous drug delivery capture the highest proportion of the global autoinjectors market. It is worth highlighting that the global autoinjector market for intravenous autoinjector segment is likely to grow at a relatively higher CAGR.
Proteins Segment Occupy the Largest Share of the Global Autoinjectors Market by Type of Molecule Delivered
Based on the type of molecule delivered, the market is segmented into antibodies, peptides, proteins, small molecules and others. At present, autoinjectors designed for the delivery of proteins hold the maximum share of the global autoinjectors market. This trend is likely to change in the foreseeable future.
By Type of Actuation Mechanism, Autoinjectors with Automatic Actuation Mechanism is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period
Based on the type of actuation mechanism, the market is segmented into manual and automatic actuation mechanism based autoinjectors. At present, autoinjectors equipped with automatic actuation mechanisms capture the highest proportion of the global autoinjectors market. Further, it is worth highlighting that the global autoinjector market for automatic actuation mechanism based autoinjectors is likely to grow at a relatively higher CAGR.
Autoinjectors with Volume Containers of 1-2 mL Account for the Largest Share of the Global Autoinjectors Market
Based on the volume of containers, the market is segmented into autoinjectors with less than 1 ml, 1-2 ml and more than 2 ml storing volumes. Currently, autoinjectors with a drug storing capacity of 1-2 ml of a drug hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the coming decade.
By End-user, Home Care Segment is Likely to Dominate the Global Autoinjectors Market
Based on the end-user, the market is segmented into home care, hospitals and clinics and ambulatory surgical centers. At present autoinjectors used in the home care segment hold the maximum share of the global autoinjectors market. Additionally, this segment is likely to grow at a faster pace, compared to the other segments.
Autoinjectors Designed for the Treatment of Rheumatoid Arthritis Occupy the Largest Share of the Global Autoinjectors Market
Based on the target indication, the market is segmented into anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and other indications. Whilst rheumatoid arthritis target indication segment is expected to be the primary driver of the overall market, it is worth highlighting that the global autoinjectors market for weight loss segment is likely to grow at a relatively higher CAGR.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. The majority share is expected to be captured by players based in North America and Europe.
Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Sizing and Opportunity Analysis